The Filings Report

Bruker Corporation

BRKRNasdaqCIK 1109354Healthcare / Diagnostics & Researchfiscal year ends December67 quarters since 2010

Revenue, Q3 FY2026
$874M
+1.6% on Q3 FY2025
Net income
−$112M
−87.6% on Q3 FY2025
Free cash flow
$97M
+278.7% on Q3 FY2025
Diluted EPS
$-0.81
−97.6% on Q3 FY2025
Revenue, TTM
$3.5B
trailing four quarters
Net margin, TTM
-3.5%
net income −$123M
Free cash flow, TTM
$245M
$342M less $97M capex
Cash and equivalents
$120M
long-term debt $1.7B, Sep 30, 2026
Shares, 12-month change
+0.5%
153M diluted weighted shares (no single count on the cover), Sep 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
$30M
0.3% of market value
Market value
$9.3B
at the close, buybacks

Latest quarter Q3 FY2026, filed November 5, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Bruker Corporation reported revenue of $874M, +1.6% on Q3 FY2025, and net loss of $112M (−87.6%). Operating margin was −10.4%. Free cash flow, operating cash flow less capital expenditures, was $97M ($118M less $22M). Diluted earnings per share were $-0.81.

Share price

Daily candlesticks from November 11, 2024 to November 9, 2026, with each earnings release marked; a release after the close marks the day it came out, so its reaction is the next candle. See this earnings season for every company’s reaction.

BRKR daily priceSplit-adjusted, US dollars; an earnings release
Nov 9, 2026O $62.30 · H $67.05 · L $61.70 · C $66.54 · +8.53% on the dayOver the range: +66.64%, Nov 10, 2025 to Nov 9, 2026
$30$40$51$61$71Nov 25Jan 26Apr 26Jun 26Aug 26Nov 26

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of November 5, 2026.

Revenue and net incomeRevenueNet income
−$500M$0$500M$1.0BQ4'22, Revenue: $708MQ4'22, Net income: $97MQ4'22Q1'23, Revenue: $685MQ1'23, Net income: $77MQ1'23Q2'23, Revenue: $682MQ2'23, Net income: $57MQ2'23Q3'23, Revenue: $743MQ3'23, Net income: $88MQ3'23Q4'23, Revenue: $855MQ4'23, Net income: $206MQ4'23Q1'24, Revenue: $722MQ1'24, Net income: $51MQ1'24Q2'24, Revenue: $801MQ2'24, Net income: $8MQ2'24Q3'24, Revenue: $864MQ3'24, Net income: $41MQ3'24Q4'24, Revenue: $980MQ4'24, Net income: $14MQ4'24Q1'25, Revenue: $801MQ1'25, Net income: $17MQ1'25Q2'25, Revenue: $797MQ2'25, Net income: $8MQ2'25Q3'25, Revenue: $861MQ3'25, Net income: −$60MQ3'25Q4'25, Revenue: $977MQ4'25, Net income: $26MQ4'25Q1'26, Revenue: $823MQ1'26, Net income: $14MQ1'26Q2'26, Revenue: $839MQ2'26, Net income: −$52MQ2'26Q3'26, Revenue: $874MQ3'26, Net income: −$112MQ3'26−$500M$0$500M$1.0BQ4'22, Revenue: $708MQ4'22, Net income: $97MQ4'22Q1'23, Revenue: $685MQ1'23, Net income: $77MQ1'23Q2'23, Revenue: $682MQ2'23, Net income: $57MQ2'23Q3'23, Revenue: $743MQ3'23, Net income: $88MQ3'23Q4'23, Revenue: $855MQ4'23, Net income: $206MQ4'23Q1'24, Revenue: $722MQ1'24, Net income: $51MQ1'24Q2'24, Revenue: $801MQ2'24, Net income: $8MQ2'24Q3'24, Revenue: $864MQ3'24, Net income: $41MQ3'24Q4'24, Revenue: $980MQ4'24, Net income: $14MQ4'24Q1'25, Revenue: $801MQ1'25, Net income: $17MQ1'25Q2'25, Revenue: $797MQ2'25, Net income: $8MQ2'25Q3'25, Revenue: $861MQ3'25, Net income: −$60MQ3'25Q4'25, Revenue: $977MQ4'25, Net income: $26MQ4'25Q1'26, Revenue: $823MQ1'26, Net income: $14MQ1'26Q2'26, Revenue: $839MQ2'26, Net income: −$52MQ2'26Q3'26, Revenue: $874MQ3'26, Net income: −$112MQ3'26−$500M$0$500M$1.0BQ4'22, Revenue: $708MQ4'22, Net income: $97MQ1'23, Revenue: $685MQ1'23, Net income: $77MQ1'23Q2'23, Revenue: $682MQ2'23, Net income: $57MQ3'23, Revenue: $743MQ3'23, Net income: $88MQ3'23Q4'23, Revenue: $855MQ4'23, Net income: $206MQ1'24, Revenue: $722MQ1'24, Net income: $51MQ1'24Q2'24, Revenue: $801MQ2'24, Net income: $8MQ3'24, Revenue: $864MQ3'24, Net income: $41MQ3'24Q4'24, Revenue: $980MQ4'24, Net income: $14MQ1'25, Revenue: $801MQ1'25, Net income: $17MQ1'25Q2'25, Revenue: $797MQ2'25, Net income: $8MQ3'25, Revenue: $861MQ3'25, Net income: −$60MQ3'25Q4'25, Revenue: $977MQ4'25, Net income: $26MQ1'26, Revenue: $823MQ1'26, Net income: $14MQ1'26Q2'26, Revenue: $839MQ2'26, Net income: −$52MQ3'26, Revenue: $874MQ3'26, Net income: −$112MQ3'26

Net income losses drawn in red.

Free cash flow
−$200M−$100M$0$100M$200M$300MQ4'22, Free cash flow: $137MQ4'22Q1'23, Free cash flow: $63MQ1'23Q2'23, Free cash flow: −$11MQ2'23Q3'23, Free cash flow: $17MQ3'23Q4'23, Free cash flow: $174MQ4'23Q1'24, Free cash flow: $400KQ1'24Q2'24, Free cash flow: −$24MQ2'24Q3'24, Free cash flow: $6MQ3'24Q4'24, Free cash flow: $153MQ4'24Q1'25, Free cash flow: $39MQ1'25Q2'25, Free cash flow: −$149MQ2'25Q3'25, Free cash flow: −$54MQ3'25Q4'25, Free cash flow: $207MQ4'25Q1'26, Free cash flow: $47MQ1'26Q2'26, Free cash flow: −$106MQ2'26Q3'26, Free cash flow: $97MQ3'26−$200M−$100M$0$100M$200M$300MQ4'22, Free cash flow: $137MQ4'22Q1'23, Free cash flow: $63MQ1'23Q2'23, Free cash flow: −$11MQ2'23Q3'23, Free cash flow: $17MQ3'23Q4'23, Free cash flow: $174MQ4'23Q1'24, Free cash flow: $400KQ1'24Q2'24, Free cash flow: −$24MQ2'24Q3'24, Free cash flow: $6MQ3'24Q4'24, Free cash flow: $153MQ4'24Q1'25, Free cash flow: $39MQ1'25Q2'25, Free cash flow: −$149MQ2'25Q3'25, Free cash flow: −$54MQ3'25Q4'25, Free cash flow: $207MQ4'25Q1'26, Free cash flow: $47MQ1'26Q2'26, Free cash flow: −$106MQ2'26Q3'26, Free cash flow: $97MQ3'26−$200M−$100M$0$100M$200M$300MQ4'22, Free cash flow: $137MQ1'23, Free cash flow: $63MQ1'23Q2'23, Free cash flow: −$11MQ3'23, Free cash flow: $17MQ3'23Q4'23, Free cash flow: $174MQ1'24, Free cash flow: $400KQ1'24Q2'24, Free cash flow: −$24MQ3'24, Free cash flow: $6MQ3'24Q4'24, Free cash flow: $153MQ1'25, Free cash flow: $39MQ1'25Q2'25, Free cash flow: −$149MQ3'25, Free cash flow: −$54MQ3'25Q4'25, Free cash flow: $207MQ1'26, Free cash flow: $47MQ1'26Q2'26, Free cash flow: −$106MQ3'26, Free cash flow: $97MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$1B$2B$3BQ4'22, Cash and equivalents: $646MQ4'22, Long-term debt: $1.2BQ4'22Q1'23, Cash and equivalents: $598MQ1'23, Long-term debt: $1.1BQ1'23Q2'23, Cash and equivalents: $575MQ2'23, Long-term debt: $1.1BQ2'23Q3'23, Cash and equivalents: $364MQ3'23, Long-term debt: $1.1BQ3'23Q4'23, Cash and equivalents: $488MQ4'23, Long-term debt: $1.2BQ4'23Q1'24, Cash and equivalents: $340MQ1'24, Long-term debt: $1.4BQ1'24Q2'24, Cash and equivalents: $170MQ2'24, Long-term debt: $2.1BQ2'24Q3'24, Cash and equivalents: $148MQ3'24, Long-term debt: $2.3BQ3'24Q4'24, Cash and equivalents: $183MQ4'24, Long-term debt: $2.1BQ4'24Q1'25, Cash and equivalents: $184MQ1'25, Long-term debt: $2.1BQ1'25Q2'25, Cash and equivalents: $92MQ2'25, Long-term debt: $2.4BQ2'25Q3'25, Cash and equivalents: $293MQ3'25, Long-term debt: $2.0BQ3'25Q4'25, Cash and equivalents: $299MQ4'25, Long-term debt: $1.9BQ4'25Q1'26, Cash and equivalents: $133MQ1'26, Long-term debt: $1.7BQ1'26Q2'26, Cash and equivalents: $185MQ2'26, Long-term debt: $1.8BQ2'26Q3'26, Cash and equivalents: $120MQ3'26, Long-term debt: $1.7BQ3'26$0$1B$2B$3BQ4'22, Cash and equivalents: $646MQ4'22, Long-term debt: $1.2BQ4'22Q1'23, Cash and equivalents: $598MQ1'23, Long-term debt: $1.1BQ1'23Q2'23, Cash and equivalents: $575MQ2'23, Long-term debt: $1.1BQ2'23Q3'23, Cash and equivalents: $364MQ3'23, Long-term debt: $1.1BQ3'23Q4'23, Cash and equivalents: $488MQ4'23, Long-term debt: $1.2BQ4'23Q1'24, Cash and equivalents: $340MQ1'24, Long-term debt: $1.4BQ1'24Q2'24, Cash and equivalents: $170MQ2'24, Long-term debt: $2.1BQ2'24Q3'24, Cash and equivalents: $148MQ3'24, Long-term debt: $2.3BQ3'24Q4'24, Cash and equivalents: $183MQ4'24, Long-term debt: $2.1BQ4'24Q1'25, Cash and equivalents: $184MQ1'25, Long-term debt: $2.1BQ1'25Q2'25, Cash and equivalents: $92MQ2'25, Long-term debt: $2.4BQ2'25Q3'25, Cash and equivalents: $293MQ3'25, Long-term debt: $2.0BQ3'25Q4'25, Cash and equivalents: $299MQ4'25, Long-term debt: $1.9BQ4'25Q1'26, Cash and equivalents: $133MQ1'26, Long-term debt: $1.7BQ1'26Q2'26, Cash and equivalents: $185MQ2'26, Long-term debt: $1.8BQ2'26Q3'26, Cash and equivalents: $120MQ3'26, Long-term debt: $1.7BQ3'26$0$1B$2B$3BQ4'22, Cash and equivalents: $646MQ4'22, Long-term debt: $1.2BQ1'23, Cash and equivalents: $598MQ1'23, Long-term debt: $1.1BQ1'23Q2'23, Cash and equivalents: $575MQ2'23, Long-term debt: $1.1BQ3'23, Cash and equivalents: $364MQ3'23, Long-term debt: $1.1BQ3'23Q4'23, Cash and equivalents: $488MQ4'23, Long-term debt: $1.2BQ1'24, Cash and equivalents: $340MQ1'24, Long-term debt: $1.4BQ1'24Q2'24, Cash and equivalents: $170MQ2'24, Long-term debt: $2.1BQ3'24, Cash and equivalents: $148MQ3'24, Long-term debt: $2.3BQ3'24Q4'24, Cash and equivalents: $183MQ4'24, Long-term debt: $2.1BQ1'25, Cash and equivalents: $184MQ1'25, Long-term debt: $2.1BQ1'25Q2'25, Cash and equivalents: $92MQ2'25, Long-term debt: $2.4BQ3'25, Cash and equivalents: $293MQ3'25, Long-term debt: $2.0BQ3'25Q4'25, Cash and equivalents: $299MQ4'25, Long-term debt: $1.9BQ1'26, Cash and equivalents: $133MQ1'26, Long-term debt: $1.7BQ1'26Q2'26, Cash and equivalents: $185MQ2'26, Long-term debt: $1.8BQ3'26, Cash and equivalents: $120MQ3'26, Long-term debt: $1.7BQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed November 5, 2026.

Bruker Corporation income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 5, 2026Q2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 7, 2026Q4 FY2025ended Dec 31, 2025filed Feb 27, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 7, 2025Q4 FY2024ended Dec 31, 2024filed Mar 3, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue874839823977861797801980+1.6%
Cost of revenue445423444528481440410486−7.6%
Gross profit429416380449379358391493+13.2%
Research and development92941011009810097104−6.4%
Selling, general and administrative227239242247243231225247−6.6%
Operating income(91)(65)1076(52)123272−75.7%
Other income (expense)(29)2512(8)(20)(11)(7)(16)−46.5%
Pretax income(120)(41)2268(72)12556−67.5%
Income tax(12)14338(14)(3)941+13.5%
Net income(112)(52)1426(60)81714−87.6%
Diluted EPS ($)(0.81)(0.41)0.02—(0.41)0.050.11—−97.6%
Diluted shares (millions)153152153—152152152——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed November 5, 2026.

Bruker Corporation balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 5, 2026Q2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 7, 2026Q4 FY2025ended Dec 31, 2025filed Feb 27, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 7, 2025Q4 FY2024ended Dec 31, 2024filed Mar 3, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents12018513329929392184183−59.2%
Short-term investments—————————
Total current assets2,1572,2252,1042,2132,3512,1632,1122,053−8.2%
Total assets5,8286,0536,1316,2416,4356,3405,9335,807−9.4%
Total current liabilities1,1721,2051,3551,2791,2681,3471,3451,281−7.6%
Long-term debt1,7031,8151,6631,8531,9842,3802,0762,062−14.2%
Total liabilities———3,731———3,992—
Stockholders’ equity———2,4572,432——1,781—
Shares outstanding (millions)—————152152152—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed November 5, 2026.

Bruker Corporation cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 5, 2026Q2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 7, 2026Q4 FY2025ended Dec 31, 2025filed Feb 27, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 6, 2025Q1 FY2025ended Mar 31, 2025filed May 7, 2025Q4 FY2024ended Dec 31, 2024filed Mar 3, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow118(77)71230(33)(127)65190+456.0%
Capital expenditures2229242321212637+2.9%
Free cash flow (CFO − capex)97(106)47207(54)(149)39153+278.7%
Depreciation and amortization5458585856565053−2.9%
Share repurchases——0000100—
Dividends paid88880888—

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 27, 2026.

Income statement

Bruker Corporation income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 27, 2026FY2024ended Dec 31, 2024filed Mar 3, 2025FY2023ended Dec 31, 2023filed Feb 29, 2024FY2022ended Dec 31, 2022filed Mar 1, 2023FY2021ended Dec 31, 2021filed Feb 28, 2022FY2020ended Dec 31, 2020filed Mar 1, 2021FY2019ended Dec 31, 2019filed Mar 27, 2020FY2018ended Dec 31, 2018filed Mar 1, 2019FY2017ended Dec 31, 2017filed Mar 16, 2018FY2016ended Dec 31, 2016filed Mar 1, 2017FY2015ended Dec 31, 2015filed Feb 29, 2016FY2014ended Dec 31, 2014filed Feb 27, 2015FY2013ended Dec 31, 2013filed Feb 27, 2014FY2012ended Dec 31, 2012filed Feb 28, 2013FY2011ended Dec 31, 2011filed Feb 29, 2012FY2010ended Dec 31, 2010filed May 9, 2011FY2009ended Dec 31, 2009filed May 9, 2011
Revenue3,4373,3662,9652,5312,4181,9882,0731,8961,7661,6111,6241,8091,8391,7911,6521,3051,115
Cost of revenue1,8591,7171,4511,2251,2081,0481,0779969508669151,0461,034962899701597
Gross profit1,5781,6501,5131,3061,210940995900816745709763805829753604518
Research and development395377295236221198188173162148146174191195177141126
Selling, general and administrative947894729607561469500445415390392451438440407301254
Operating income68253437433413248301262220182146105148156156156137
Other income (expense)(46)(46)107(19)(20)(22)(20)(18)(22)(4)(18)(4)(24)(18)(10)(6)1
Pretax income22207544414394226280245198178128101125138146150129
Income tax29911181161136482641182323424360525348
Net income(9)11342729727715819718079154102578078929581
Diluted EPS ($)(0.15)0.762.901.991.811.021.261.140.490.950.600.330.480.460.550.580.49
Diluted shares (millions)1521501470*0*0*0*157159162169170169167167166165

Balance sheet

Bruker Corporation balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 27, 2026FY2024ended Dec 31, 2024filed Mar 3, 2025FY2023ended Dec 31, 2023filed Feb 29, 2024FY2022ended Dec 31, 2022filed Mar 1, 2023FY2021ended Dec 31, 2021filed Feb 28, 2022FY2020ended Dec 31, 2020filed Mar 1, 2021FY2019ended Dec 31, 2019filed Mar 27, 2020FY2018ended Dec 31, 2018filed Mar 1, 2019FY2017ended Dec 31, 2017filed Mar 16, 2018FY2016ended Dec 31, 2016filed Mar 1, 2017FY2015ended Dec 31, 2015filed Feb 29, 2016FY2014ended Dec 31, 2014filed Feb 27, 2015FY2013ended Dec 31, 2013filed Feb 27, 2014FY2012ended Dec 31, 2012filed Feb 28, 2013FY2011ended Dec 31, 2011filed Feb 29, 2012FY2010ended Dec 31, 2010filed May 9, 2011FY2009ended Dec 31, 2009filed May 9, 2011
Cash and equivalents2991834886461,068682678322325342267320439311246230207
Short-term investments———01005070114————————
Total current assets2,2132,0532,1642,1132,4721,9251,7961,3041,3591,2761,2321,3661,4321,3101,1941,051—
Total assets6,2415,8074,2503,6123,6503,0492,7722,1291,9491,8081,7301,8651,9881,8561,7111,550—
Total current liabilities1,2791,2811,202914939792646599525525555583649682756832—
Long-term debt1,8532,0621,1601,2011,222842813323———355355337303301—
Total liabilities3,7313,9922,8372,480—————————————
Stockholders’ equity2,4571,7811,3771,1141,071961907897725686726766846707622525—
Shares outstanding (millions)—152138147151152154157156160163169168167166——

Cash flow statement

Bruker Corporation cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 27, 2026FY2024ended Dec 31, 2024filed Mar 3, 2025FY2023ended Dec 31, 2023filed Feb 29, 2024FY2022ended Dec 31, 2022filed Mar 1, 2023FY2021ended Dec 31, 2021filed Feb 28, 2022FY2020ended Dec 31, 2020filed Mar 1, 2021FY2019ended Dec 31, 2019filed Mar 27, 2020FY2018ended Dec 31, 2018filed Mar 1, 2019FY2017ended Dec 31, 2017filed Mar 16, 2018FY2016ended Dec 31, 2016filed Mar 1, 2017FY2015ended Dec 31, 2015filed Feb 29, 2016FY2014ended Dec 31, 2014filed Feb 27, 2015FY2013ended Dec 31, 2013filed Feb 27, 2014FY2012ended Dec 31, 2012filed Feb 28, 2013FY2011ended Dec 31, 2011filed Feb 29, 2012FY2010ended Dec 31, 2010filed May 9, 2011FY2009ended Dec 31, 2009filed May 9, 2011
Operating cash flow134251350274282332213240154131229——————
Capital expenditures9111510712992977349443734345073623216
Free cash flow (CFO − capex)4313624314519023514019111194195——————
Depreciation and amortization2201841158989807665645453606159533630
Share repurchases100152263153123142—15216090——————
Dividends paid23302930242525252526———————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 9, 2024 to November 9, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$419K
3 sales by 2 insiders; officers and directors $419K
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$3M
15 sales by 3 insiders; officers and directors $3M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Sep 15, 2026Munch MarkEXEC VP&PRES BRUKER NANO INC.option exercise2,000$22.19$44K136,806Sep 16, 2026
Sep 15, 2026Munch MarkEXEC VP&PRES BRUKER NANO INC.open-market sale2,000$52.87$106K134,806Sep 16, 2026
Aug 17, 2026Pusch WolfgangPresident BMID Groupopen-market sale3,473$56.90$198K9,801Aug 18, 2026
Aug 15, 2026Prause BurkhardPRES. & CEO, BRUKER BESTaward3,303$0.00—28,461Aug 18, 2026
Aug 15, 2026Pusch WolfgangPresident BMID Groupaward3,120$0.00—13,274Aug 18, 2026
Aug 15, 2026Bures ThomasChief Accounting Officeraward4,035$0.00—7,233Aug 18, 2026
Aug 15, 2026Srega JuergenPRESIDENT CALIDaward16,898$0.00—174,625Aug 18, 2026
Aug 15, 2026Laukien Frank HPRESIDENT & CEO, Director, 10% owneraward29,463$0.00—39MAug 18, 2026
Aug 15, 2026Laukien Frank HPRESIDENT & CEO, Director, 10% ownertax withholding4,760$57.70$275K39MAug 18, 2026
Aug 15, 2026Herman Gerald NEXECUTIVE VICE PRESIDENT, CFOaward15,794$0.00—114,078Aug 18, 2026
Aug 15, 2026Herman Gerald NEXECUTIVE VICE PRESIDENT, CFOtax withholding2,724$57.70$157K111,354Aug 18, 2026
Aug 15, 2026Munch MarkEXEC VP&PRES BRUKER NANO INC.award14,443$0.00—137,790Aug 18, 2026
Aug 15, 2026Munch MarkEXEC VP&PRES BRUKER NANO INC.tax withholding2,984$57.70$172K134,806Aug 18, 2026
Aug 14, 2026Munch MarkEXEC VP&PRES BRUKER NANO INC.option exercise2,000$22.19$44K125,347Aug 18, 2026
Aug 14, 2026Munch MarkEXEC VP&PRES BRUKER NANO INC.open-market sale2,000$57.60$115K123,347Aug 18, 2026
Aug 11, 2026Munch MarkEXEC VP&PRES BRUKER NANO INC.tax withholding1,619$57.02$92K123,347Aug 13, 2026
Aug 11, 2026Herman Gerald NEXECUTIVE VICE PRESIDENT, CFOtax withholding1,410$57.02$80K98,284Aug 13, 2026
Aug 11, 2026Laukien Frank HPRESIDENT & CEO, Director, 10% ownertax withholding4,838$57.02$276K38MAug 13, 2026
Aug 10, 2026Munch MarkEXEC VP&PRES BRUKER NANO INC.tax withholding1,573$56.32$89K124,966Aug 11, 2026
Aug 10, 2026Herman Gerald NEXECUTIVE VICE PRESIDENT, CFOtax withholding1,289$56.32$73K99,694Aug 11, 2026
Aug 10, 2026Laukien Frank HPRESIDENT & CEO, Director, 10% ownertax withholding4,564$56.32$257K38MAug 11, 2026
Aug 9, 2026Munch MarkEXEC VP&PRES BRUKER NANO INC.tax withholding1,904$53.41$102K126,539Aug 11, 2026
Aug 9, 2026Herman Gerald NEXECUTIVE VICE PRESIDENT, CFOtax withholding1,600$53.41$85K100,983Aug 11, 2026
Aug 9, 2026Laukien Frank HPRESIDENT & CEO, Director, 10% ownertax withholding2,361$53.41$126K38MAug 11, 2026
Jul 15, 2026Munch MarkEXEC VP&PRES BRUKER NANO INC.option exercise2,000$22.19$44K130,443Jul 16, 2026

Full insider history for Bruker Corporation, or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
BRUKER CORPORATION, CIK 1109354 on EDGAR
Extract generated
November 8, 2026
Withheld
none
Repaired
1 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: other income FY2016
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues
Cost of revenue: CostOfRevenue
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense, OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss, NetIncomeLossAvailableToCommonStockholdersBasic
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: ShortTermInvestments
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt, LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividends, PaymentsOfDividendsCommonStock

The data

The statements on this page as files, generated November 8, 2026.

JSON file
/data/financials/BRKR.json